Objective: evaluate the metabolic impact and metrics of the new hybrid closed loop insulin delivery system on the quality of life in patients with type 1 diabetes.

Methods: Metrics obtained with CGM with >80% of CGM readings over a 4-week period in real life: Time in Range (TIR%) [target 70-180 mg/Dl (3.9-10mmol/L) ], Time Above Range (TAR%) [ (>180mg/dl (>10mmol/L) ], Time Below Range (TBR%) [<70mg/dl (3.9mmol/L) ], CV (<36%) referred to 30 consecutive days. Statistics ANOVA post-hoc Bonferroni/Tukey tests were used as appropriate.

Results: Fifty-two type 1 diabetic patients (38F; 14M) on SAP therapy aged 45.5±12.0 yrs, BMI 27.7±15.5 kg/m2, duration of diabetes 24.6±13.4 yrs, were studied. In these patients, who were treated with total daily insulin (TDI) 0.55±0.16 UI/kg/day, basal 0.27±0.UI/kg/day, bolus 0.28±0.UI/kg/day, mean glucose was 158.6 mg/dl (8.8 mmol/L) (121-250) , TIR% 62.4±13.5%, TBR% 4.6±4.5%, TAR% 33.0±15.1%, CV% 36.1±5.2%. Only 19 of 52 patients reached TIR≥70%. A subgroup of 30 patients (21F; 9M) , mean age 44.2±12.2 yrs, BMI 29.2±19.7 kg/m2, duration of diabetes 24.2±13.6 yrs, HbA1c 7.7±1.4%, TDI 0.59±0.14 UI/kg/day, basal 0.30 UI/kg/day, bolus 0.29 UI/kg/die, shifted from SAP to HCL. CGM Metrics regarding our patient's glucose status at baseline and 1, 2, 3, 6 and 12 months after, showed that: mean sensor BG decreased from 158.6 mg/dl (8.8 mmol/L) at baseline to 144.3 mg/dl (8.2mmol/L, p<0.05) at the 2nd month, p<0.05. TIR% significantly increased from 62.4% (TBR 4.6%, TAR 33.0%, CV 36.1%) to 76% at the first month, to 76.5% (TBR 2.6%, TAR 20.9%, CV 33%) at the 3rd month, p<0.05. After 12 months (n=10) TIR% was 73.4±8.8%, TBR% 2.7±3.1%, TAR% 23.9±7.2%, CV% 35.5±5.2%, p<0.05.

Conclusions: HCL improves glucose status increasing TIR% and reducing TAR%, TBR% and glycemic variability, improving the quality of life.


A.Convertino: None. C.Giuliani: None. O.Bitterman: None. A.Napoli: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.